Full-Time

Robotics Field Engineer

Multiply Labs

Multiply Labs

51-200 employees

Tech-driven personalized supplements via DTC subscription

Compensation Overview

$90k - $160k/yr

+ Equity

H1B Sponsorship Available

Los Angeles, CA, USA

In Person

5–10% domestic and international travel may be required.

Category
Mechanical Engineering (2)
,
Required Skills
Python
Requirements
  • Bachelor’s degree in Engineering (Mechanical, Electrical, Software), Robotics, or a related discipline.
  • 2+ years of professional experience in field engineering, system integration, or a related technical role.
  • Familiarity with Python, with the ability to read code and write basic scripts for testing and automation.
  • Mechanical aptitude with the ability to troubleshoot electromechanical systems and identify hardware vs. software root causes.
  • Excellent organizational skills and the ability to manage complex schedules in a fast-paced startup environment.
  • Strong communication skills, capable of bridging the gap between technical engineering teams and operational goals.
Responsibilities
  • Technical Troubleshooting & Scripting: Leveraging Python to develop and execute basic testing scripts for validation, assisting the software team in isolating bugs and verifying fixes in a real-world environment.
  • System Triage & Recovery: Serving as the first line of defense for the robotic cluster, executing software recovery procedures, and utilizing mechanical familiarity to identify potential error causes.
  • Issue Tracking & Communication: Developing and maintaining error tracking systems to identify trends. You will provide organized, proactive communication regarding cluster issues, needs, and status updates to both internal stakeholders and on-site partners.
  • Cluster Operations & Scheduling: Detailed planning of daily cluster schedules at the deployment site, aligning closely with engineering, product teams, and customer partners to set testing timelines and ensure optimal system utilization.
Desired Qualifications
  • Familiarity with AWS deployments, managing production environments, and troubleshooting cloud-connected hardware.
  • Experience with laboratory automation or working in GxP/regulated environments.
  • Experience using data visualization tools (e.g., Grafana, Tableau) to monitor cluster performance and reliability trends.

Multiply Labs creates personalized vitamins and supplements using a proprietary tech platform that analyzes factors like age, lifestyle, and health goals to design a customized regimen. Products are sold directly to consumers through multiplylabs.com, typically on a subscription, enabling ongoing, data-informed adjustments. The approach combines science-based customization with a direct-to-consumer model to deliver precise nutrition for fitness enthusiasts and people with specific dietary needs, aiming for steady growth and better health outcomes.

Company Size

51-200

Company Stage

Series A

Total Funding

$23M

Headquarters

San Francisco, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • $85M Retro Biosciences deal marks first commercial robotic sale.
  • Partnerships with AstraZeneca, Legend Biotech expand cell therapy market.
  • 74% cost reduction, 100x more doses per cleanroom square foot.

What critics are saying

  • Retro Biosciences fails trials in 18-36 months, collapsing $85M revenue.
  • No funding since April 2023 $2M round causes insolvency in 12-24 months.
  • Legend Biotech builds in-house robotics in 6-18 months, ending collaboration.

What makes Multiply Labs unique

  • Multiply Labs pioneered 3D printed personalized pharmaceutical capsules.
  • Robotic systems automate cell therapy manufacturing end-to-end.
  • Cloud-controlled clusters mimic lab workflows via imitation learning.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Multiply Labs who can refer or advise you

Benefits

Work from home option

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-5%

2 year growth

-5%
Business Wire
Jan 27th, 2026
Multiply Labs partners with AstraZeneca to automate cell therapy manufacturing with robotics

Multiply Labs has announced an agreement with AstraZeneca to evaluate GMP-ready robotic systems for commercial-scale cell therapy manufacturing. The collaboration will focus on end-to-end robotic automation of industry-standard instruments using Multiply Labs' biomanufacturing platform. The San Francisco-based robotics company develops autonomous manufacturing technology for advanced therapies. Its newest systems use four robotic arms operating in parallel to run cell therapy manufacturing instruments, aiming to maximise output whilst minimising process modifications. "Cell therapies are among the most promising, yet complex medicines being developed today," said Fred Parietti, CEO of Multiply Labs. "Our mission is to make these therapies more widely available by increasing manufacturing efficiency and scale." The collaboration seeks to enable scalable, high-throughput manufacturing whilst maintaining quality and regulatory standards for clinical and commercial use.

Stock Titan
Sep 24th, 2024
Multiply Labs Announces a Collaboration on Automating Cell Therapy Manufacturing with Legend Biotech

Multiply Labs, a robotics company specializing in automated manufacturing systems for individualized drugs, has announced a collaboration with Legend Biotech (NASDAQ: LEGN).

RegMedNet
May 23rd, 2024
Cell therapy weekly: Funding supports remyelination therapy for multiple sclerosis

Progentos Therapeutics, a biotech company developing a novel regenerative medicine for multiple sclerosis (MS), has launched after securing US$65 million in Series A funding.

Business Wire
May 21st, 2024
Portal Biotechnologies And Multiply Labs Announce Partnership To Automate Cell Engineering In Cell Therapy Manufacturing

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Multiply Labs and Portal Biotechnologies announced their collaboration today, combining the efficiency of Multiply Labs’ robotic automation with the differentiated cell engineering capabilities of the Portal platform. This collaboration is an important step forward for cell therapy development and manufacturing with the goal of leveraging automation to accelerate product timelines and reduce costs, helping innovative cell therapies reach more patients. “Cell therapy manufacturing infrastructure and its associated costs have severely limited the accessibility of cell therapies. Multiply Labs’ automation strategy has the potential to modularize and simplify cell therapy production to ensure greater patient impact. We are very excited to contribute to the Multiply Labs team’s vision by integrating our next generation cell engineering approach with their robotics,” said Armon Sharei, Founder and CEO of Portal. Portal’s mechanoporation technology has demonstrated the capability to deliver many different types of cargo to a broad range of cell types while preserving normal cell function

Longevity.Technology
May 15th, 2024
Multiply Labs inks $85m deal with Retro Bio to automate cell therapy manufacturing

Longevity biotech Retro Biosciences has entered into an $85 million agreement with Multiply Labs to enhance the production of its cell therapies aimed at age-related diseases.